Back to top
more

Medpace (MEDP)

(Real Time Quote from BATS)

$429.45 USD

429.45
149,489

-6.85 (-1.57%)

Updated Aug 6, 2025 12:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (73 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Teladoc Up 33% Year to Date: Will the Momentum Continue?

by Zacks Equity Research

Teladoc's (TDOC) vast business presence in the growing telehealth industry with many deal wins and international expansion should drive long-term growth.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Industrial Logistics, Medpace, Unitil, DaVita and Telephone and Data

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Industrial Logistics, Medpace, Unitil, DaVita and Telephone and Data

Nalak Das headshot

5 Stocks to Buy on a Possible Second Rate Cut in September

by Nalak Das

As signs of deterioration emerge, the central bank may feel compelled to cut rate for the second time in September.

Zacks Equity Research

Medpace Holdings, Inc. (MEDP) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Medpace Holdings, Inc. (MEDP).

Zacks Equity Research

Medpace (MEDP) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Medpace (MEDP) delivered earnings and revenue surprises of 28.57% and 6.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Can Medpace (MEDP) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Medpace (MEDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Medpace (MEDP) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Urmimala Biswas headshot

Near-Term Outlook for Medical Services Industry Looks Bright

by Urmimala Biswas

The third-party medical services industry is expanding rapidly.

Zacks Equity Research

Ensign Group (ENSG) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Ensign Group (ENSG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

TVTY vs. MEDP: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

TVTY vs. MEDP: Which Stock Is the Better Value Option?

Zacks Equity Research

Medpace (MEDP) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Medpace (MEDP) delivered earnings and revenue surprises of 10.14% and 4.04%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Medpace (MEDP) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

What's in Store for Teladoc in 2019, After a Strong 2018?

by Zacks Equity Research

Teladoc (TDOC) should continue to gain from increasing demand for its services and global expansion.

Zacks Equity Research

Cigna Poised for Growth in 2019 on Express Scripts Buyout

by Zacks Equity Research

The purchase of Express Scripts by Cigna (CI) has diversified its business, which should fuel long-term growth.

Zacks Equity Research

MEDP or HQY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

MEDP vs. HQY: Which Stock Is the Better Value Option?

Zacks Equity Research

The Zacks Analyst Blog Highlights: Anthem, Ensign, NeoGenomics, Merit Medical Systems and Medpace

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Anthem, Ensign, NeoGenomics, Merit Medical Systems and Medpace

Zacks Equity Research

5 Healthcare Bets to Stay in Investors Good Books Next Year

by Zacks Equity Research

Based on a few key factors, we zero in on five stocks that show promise to retain the bull run in 2019.

Zacks Equity Research

Teladoc (TDOC) Surges 64% in a Year: Can the Rally Continue?

by Zacks Equity Research

Teladoc (TDOC) is poised to grow on accelerating demand for its telehealth services.

Zacks Equity Research

PRA Health Sciences (PRAH) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

PRA Health Sciences (PRAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

BioTelemetry (BEAT) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

BioTelemetry (BEAT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

MEDP vs. PRAH: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

MEDP vs. PRAH: Which Stock Is the Better Value Option?

Zacks Equity Research

BioTelemetry (BEAT) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

BioTelemetry (BEAT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Express Scripts (ESRX) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Express Scripts (ESRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

MEDP vs. PRAH: Which Stock Is the Better Value Option?

by Zacks Equity Research

MEDP vs. PRAH: Which Stock Is the Better Value Option?

Zacks Equity Research

Medpace (MEDP) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Medpace (MEDP) delivered earnings and revenue surprises of 6.35% and 2.39%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?